Specialized GPCR Heteromer Inhibitors for Niche Applications

Publication ID: 24-11857600_0004_PTD
Published: October 28, 2025
Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Specialized GPCR Heteromer Inhibitors for Niche Applications,” Published Technical Disclosure No. 24-11857600_0004_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857600_0004_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,600.

Summary of the Inventive Concept

This inventive concept adapts GPCR heteromer inhibitors for specific, high-need markets, such as high-security facilities, disaster relief, extreme weather conditions, remote areas, and high-altitude areas.

Background and Problem Solved

The original patent disclosed GPCR heteromer inhibitors for cancer treatment, but these inhibitors may not be suitable for unique operational environments. This inventive concept addresses the need for specialized inhibitors that can effectively treat cancer in these niche markets.

Detailed Description of the Inventive Concept

The new inventive concept involves adapting CXCR4-HRH1 heteromer inhibitors for specific use cases, such as high-security facilities, disaster relief, extreme weather conditions, remote areas, and high-altitude areas. For example, the inhibitor may be formulated for administration in extreme weather conditions or packaged with secure data storage units for high-security facilities. The inventive concept also encompasses systems and kits that integrate these inhibitors with specialized equipment, such as satellite communication devices and weather-resistant containers, to ensure effective treatment in these unique environments.

Novelty and Inventive Step

The new claims introduce novel, specialized variations of GPCR heteromer inhibitors that are tailored to specific, high-need markets. The inventive step lies in the recognition of these niche markets and the adaptation of the original inhibitors to meet their unique requirements.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include adapting the inhibitors for use in other niche markets, such as space exploration or military operations. Variations could include different formulations, dosing regimens, or packaging configurations tailored to specific use cases.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, particularly in the areas of cancer treatment and niche market applications. Target industries include healthcare providers, pharmaceutical companies, and government agencies involved in disaster relief and high-security operations.

CPC Classifications

SectionClassGroup
A A61 A61K38/195
A A61 A61K31/138
A A61 A61K31/395
A A61 A61K31/403
A A61 A61K31/451
A A61 A61K31/4545
A A61 A61K31/47
A A61 A61K31/495
A A61 A61K31/5415
A A61 A61K38/12
A A61 A61K39/3955
A A61 A61P35/00
C C07 C07K16/286
C C07 C07K16/2866
A A61 A61K2039/505
A A61 A61K2039/507
C C07 C07K2317/21
C C07 C07K2317/76

Field of Art

Pharmaceutical biotechnology with specialization in G protein-coupled receptor (GPCR) heteromer inhibitors, cancer therapeutics, and drug delivery systems. Requires advanced knowledge of molecular pharmacology, receptor interactions, and pharmaceutical formulation techniques

Person of Ordinary Skill (PHOSITA) Profile

A PhD-level researcher with expertise in molecular pharmacology, experience in GPCR heteromer characterization, drug development, and formulation strategies. Capable of understanding complex receptor interactions and adapting therapeutic approaches to specialized environments

Obviousness Rationale

A PHOSITA would recognize that the core CXCR4-HRH1 heteromer inhibitor technology can be readily adapted to different environmental contexts by applying standard pharmaceutical engineering principles. The fundamental molecular mechanism remains unchanged, with variations primarily involving formulation, packaging, and delivery strategies. These adaptations represent predictable extensions of the original therapeutic concept that would be obvious to a skilled practitioner in the field.

Obvious Combinations & Variations

Source Patent Element
CXCR4-HRH1 heteromer inhibitor for cancer treatment
PTD Variation
Formulating inhibitor for administration in extreme weather conditions
Obviousness Reasoning
Pharmaceutical formulation techniques for maintaining drug stability under variable environmental conditions are well-established and represent a routine design optimization for a PHOSITA
Source Patent Element
Cancer treatment method involving receptor interaction inhibition
PTD Variation
Integrating inhibitor administration with remote monitoring systems
Obviousness Reasoning
Telemedicine and remote patient monitoring are standard practices in modern medical treatment, representing a predictable technological extension
Source Patent Element
Calcium mobilization modulation in CXCR4-HRH1 heteromers
PTD Variation
High-altitude physiological adaptation of inhibitor formulation
Obviousness Reasoning
Adjusting pharmaceutical compositions to account for physiological variations is a standard practice in drug development, particularly for treatments in challenging environmental conditions
Source Patent Element
Cancer treatment method targeting specific receptor heteromers
PTD Variation
Secure data storage integration with treatment protocol
Obviousness Reasoning
Combining medical treatments with data management systems is a predictable technological convergence in modern healthcare delivery
Source Patent Element
GPCR heteromer inhibition mechanism
PTD Variation
Disaster relief and emergency medical deployment strategies
Obviousness Reasoning
Adapting pharmaceutical interventions for emergency and humanitarian contexts represents a logical extension of existing medical technology
35 U.S.C. § 103 Summary: Pursuant to 35 U.S.C. ยง 103, the variations disclosed in this publication would have been obvious to a person having ordinary skill in the art at the time of invention, with a reasonable expectation of success, based on the foundational teachings of US Patent 11857600 regarding CXCR4-HRH1 heteromer inhibition. The disclosed adaptations represent predictable variations that would be readily conceived by a skilled practitioner without requiring undue experimentation.

Original Patent Information

Patent NumberUS 11,857,600
TitleGPCR heteromer inhibitors and uses thereof
Assignee(s)GPCR THERAPEUTICS, INC.